Integrated BioTherapeutics, Inc.

Dr. M. Javad Aman
President and CSO
Integrated BioTherapeutics, Inc. (IBT)
Our Company

Mission

Develop vaccines and therapeutics for infectious agents

Emphasis on:

• Biodefense Market (Filoviruses: Ebola and Marburg)

• Emerging Infectious Diseases (Staph)
Company History

- Founded
- 1st License Agreement
- Lab space at FITCI
- DoD Funding SEB Vaccine
- NIH approved Clinical Trial
- NIAID, Filovirus VLP vaccine
- NIH UO1 SEB HuMAb

- 1st Funding TEDCO FDTTI
- DoD Funding VHF Therapeutics
- Army SBIR II SEB Therapeutic

- $0
- $50K
- $3.1M
- $3.5M
- $5.4M
- $10M
- $32M

- # of F/T Employees
- Cumulative Funding Secured

- May-05
- Oct-05
- Mar-06
- Aug-06
- Jan-07
- Jun-07
- Nov-07
- Apr-08
- Sep-08
- Feb-09
- Jul-09
A Growing Maryland Business

May 2008
IBT wins Incubator Company of the Year award for “Best Life Sciences Company”

June 2008
- IBT graduates from FITCI business incubator
- IBT moves into Avalon facility in Germantown

May 2009
The Tech Council of Maryland Awards IBT the “Emerging Company of the Year” for the state of Maryland
IBT Partnerships: Funding, Collaborations and Partnerships
**Recombinant Vaccines** for Staphylococcal and Streptococcal Exotoxins

- STEBVax IND- Biodefense
- SEB-HIG Preclinical- Biodefense
- TSS-HIG Preclinical- Toxic Shock, Sepsis
- SEB-HuMab Preclinical- Biodefense

**Virus-Like Particle Vaccines** for
- Filoviruses (Ebola & Marburg)
- Arenaviruses (Lassa & Junin)
- Bunyaviruses (RVFV)
IBT Product Pipeline

**Vaccines**
- FiloVax: Panfilovirus VLP vaccine
- STEBVax: Recombinant SEB vaccine
- Multivalent Staph Vaccine

**Therapeutics**
- SEB-HIG: HyperImmune Globulin Therapeutic to SEB
- SEB-HuMab: Human Monoclonal Ab Therapeutic
- TSS-HIG: Toxic shock syndrome Therapeutic
IBT was a four person company at the time

Primary Writers:

Dr. Javad Aman – Founder of IBT
Dr. Kelly Warfield (then at USAMRIID)

IBT’s Advantage: Superior technology and data to show it.

IBT’s Challenges: Young company/ limited infrastructure

The Solution: Build a team to enhance capabilities

*IBT secured a team of subcontractors to win the proposal*
NIAID Contract
Development Plan

Base Period – 4 years, ~ $22 M in funding
- Assay Development
- Scale Up and Process Development
- Formulation and Stability
- Bridging, Efficacy, and Immune Correlate Studies

Options Phase - ~43 M in Funding
- cGMP Manufacturing and IND
- Phase I Dose Escalation Safety Clinical Trial
- 200,000 Dose Manufacturing
- Lyophylized Formulation
- Phase II Immunogenicity Clinical Trial
FiloVax Program

- Recognized expertise in Filovirus research
- Very strong technical knowledge of the technology and model
- Original inventors of the Army’s Filovirus VLP Vaccine Candidate
- Ongoing partnership via CRADAs with USAMRIID team to develop VLP vaccine
Special Thanks to:

Maryland TEDCO

The National Institute of Allergy and Infectious Diseases and NIH